Oscar Health, Inc. (OSCR)

Executive Summary / Key Takeaways

• The 2026 Profitability Inflection Is Credible: After a 2025 that produced a $443M net loss due to industry-wide morbidity shocks, Oscar's 2026 guidance projects a $250-450M operating profit swing driven by 61% revenue growth, 450 basis points of MLR improvement, and 140 basis points of SG&A leverage, representing nearly $750M in earnings improvement at the midpoint.

• Technology Moat Creates Structural Cost Advantage: While competitors struggle with scale, Oscar's AI health agent Oswell now resolves 86% of member questions with high accuracy, enabling a 160 basis point SG&A ratio improvement to 17.5% in 2025 despite 22% membership growth, demonstrating a variable cost structure that improves with scale.

• Market Share Gains Are Defensive, Not Speculative: Oscar's footprint share jumped from 17% to 30% in 2026 not through aggressive pricing but as competitors priced themselves out or exited entirely, allowing disciplined 28% rate increases that preserve margins while capturing 3.4M members—validating the stickiness of its tech-enabled value proposition.

• Balance Sheet Strength Provides Strategic Optionality: With $5.5B in cash and investments, $1B in insurance subsidiary surplus, and a new $475M credit facility, Oscar holds virtually no leverage and sufficient capital to absorb 2025's shocks while funding the 58% membership expansion and $60M in cost reduction initiatives for 2026.

• Critical Risk Concentration in Risk Adjustment: The $275M Q4 2025 risk adjustment true-up reveals Oscar's single largest vulnerability—estimating its own healthiness relative to the market remains a complex quarterly requirement, and 2026's projected 20% risk adjustment payable represents a 150 basis point increase that could swing results by hundreds of millions if market morbidity estimates prove wrong.

Setting the Scene: The ACA Individual Market's Tech Disruptor

Oscar Health, founded in 2012 and headquartered in New York City, began with a simple but radical premise: rebuild health insurance from the ground up using technology to make healthcare accessible, affordable, and intuitive. Unlike legacy insurers who bolt digital tools onto decades-old administrative infrastructure, Oscar built a cloud-native platform where every member interaction—from plan selection to claims processing—flows through a unified data architecture. This matters because it creates a fundamentally different cost structure and member experience, one where AI can automate routine tasks, predictive analytics can guide care decisions, and a single member record can power both insurance operations and provider partnerships.

The company operates as a single reportable segment but functions across three integrated activities: Oscar's Insurance Business (ACA individual and family plans), the Oscar Platform (Campaign Builder technology licensing to other payors), and Brokerage Services (the 2025 acquisitions of Lucie, IHC Specialty Benefits, and Healthinsurance.org to support ICHRA expansion). This structure diversifies revenue while creating a flywheel: insurance membership funds platform development, platform licensing validates the technology for enterprise clients, and brokerage capabilities create a direct enrollment channel that reduces customer acquisition costs.

Oscar's place in the industry structure reveals both opportunity and fragility. The ACA individual market serves approximately 22 million Americans, a population that powers the economy yet faces constant affordability pressures. The market is dominated by behemoths like UnitedHealth (UNH) (16% national share), Elevance (ELV) (12%), and Centene (CNC) (10-12%), who leverage scale to extract provider discounts and spread administrative costs across tens of millions of members. Oscar's sub-1% national share would normally relegate it to insignificance, but its 30% footprint share in 2026 demonstrates a different dynamic: in its chosen markets, Oscar has become a material player by targeting the tech-savvy, digitally-native consumer that legacy insurers struggle to serve.

The 2025 reset moment fundamentally altered this landscape. When Medicaid redeterminations pushed millions into the individual market and CMS program integrity initiatives exposed adverse selection, industry-wide morbidity increased 1.5-2 points. This matters because risk adjustment—the mechanism that transfers funds from insurers with healthier members to those with sicker ones—became a zero-sum game where misestimating relative healthiness creates massive financial volatility. Oscar's 87.4% MLR in 2025, up 570 basis points, wasn't a company-specific failure but an industry-wide phenomenon that forced every carrier to reprice. The implication is profound: 2026 becomes a test of whether Oscar's technology can create a durable advantage in a market where everyone is raising rates and tightening underwriting.

Technology, Products, and Strategic Differentiation

Oscar's core technology advantage centers on its proprietary platform, which integrates AI across every operational layer. Oswell, the industry-first health AI agent powered by OpenAI, now completes 86% of member questions with high accuracy and quality. This matters because it directly addresses health insurance's largest cost driver: administrative expense. While legacy insurers staff call centers with thousands of agents, Oscar's AI handles the routine, allowing human care guides to focus on complex cases. The 160 basis point SG&A improvement in 2025 to 17.5%—the lowest quarterly ratio in company history at 15.8% in Q1—demonstrates that technology creates genuine operating leverage.

Campaign Builder, the Oscar Platform's engagement engine, serves nearly 0.6 million client lives beyond Oscar's own membership. This matters because it transforms Oscar from a pure insurer into a technology vendor, generating $28.6M in other revenues while proving the platform's value to external payors. When competitors license your technology, it validates the moat and creates a revenue stream that isn't subject to medical cost volatility. The platform uses predictive analytics to identify high-value engagement opportunities, delivering personalized interactions that improve care and reduce costs. This creates a dual benefit: better health outcomes lower the MLR, while the data feedback loop improves the AI models, making the platform more valuable to both Oscar and its clients.

The 2025 acquisitions of Lucie (direct enrollment technology), IHC Specialty Benefits (individual market brokerage), and Healthinsurance.org (consumer education) represent a strategic stacking of capabilities for the ICHRA market. This matters because ICHRA—allowing employers to reimburse employees for individual market premiums—could disrupt traditional group coverage and expand Oscar's addressable market beyond the ACA's 22 million. Lucie's status as one of only 11 CMS-approved direct enrollment solutions gives Oscar a regulatory moat, while IHC's 50-state brokerage footprint provides distribution scale that would take years to build organically. The Hy-Vee Health with Oscar partnership in Des Moines exemplifies the strategy: a $0 concierge-type care plan with in-store rewards for healthy food purchases, creating a differentiated product that traditional insurers can't replicate without rebuilding their entire technology stack.

Product innovation extends to condition-specific lifestyle offerings like Hello Meno (the first menopause plan in the ACA) and Cuando Salud (Spanish-first diabetes experience). These matter because they target underserved niches with above-average retention rates and 50% higher recommendation likelihood. In a market where customer acquisition costs are rising and churn is a constant threat, products that create emotional loyalty and word-of-mouth growth are economically transformative. They also attract younger, healthier members—Oscar's 2026 average member is one year younger than 2025's—improving risk adjustment positioning and reducing MLR pressure.

Financial Performance & Segment Dynamics: 2025 as Strategic Reset

Oscar's 2025 financial results must be viewed as a deliberate repositioning. The $11.7B total revenue, up 28% year-over-year, demonstrates that even in a crisis year, Oscar's value proposition resonated with consumers. The $443M net loss primarily reflects a $275M Q4 risk adjustment true-up when Oscar's membership skewed healthier than the broader market. This matters because it reveals the mathematical impact of risk adjustment: being healthier than expected means paying more into the pool. The 570 basis point MLR increase to 87.4% wasn't from claims spiraling out of control but from this transfer payment mechanism, which is zero-sum across the industry.

The quarterly progression tells a more nuanced story. Q1 2025 produced $329M in adjusted EBITDA and a 75.4% MLR, but this included a $31M unfavorable prior period development from 2024 risk adjustment. Q3 saw the MLR climb to 88.5% with a $130M risk adjustment increase, partially offset by $84M in favorable prior period development. Q4's 95.4% MLR spike was vastly driven by the risk adjustment true-up, not utilization catastrophe. This matters because it shows Oscar's underlying claims management remained disciplined even as the market destabilized. The $99M of favorable in-year development and $36M of favorable prior period development in Q4 demonstrate that actual medical costs were under control.

The SG&A ratio improvement to 17.5% for the full year, from 19.1% in 2024, is a significant financial signal. In a year when membership grew 22% to 2M effectuated members, and when the company expanded broker partnerships by 60%, administrative costs grew slower than revenue. This matters because it proves the technology moat is real. Fixed cost leverage contributed 40% of the Q1 improvement, variable cost structure improvements added 15%, and the remainder came from broker taxes and risk adjustment geography optimization. The implication is structural: Oscar's cost per member declines as it scales, the opposite of legacy insurers whose administrative costs rise with complexity.

The balance sheet provides crucial context for the 2026 pivot. Oscar ended 2025 with $5.5B in cash and investments, including $414M at the parent. Insurance subsidiaries held $1B in capital surplus with $315M in excess capital. Richard Blackley's statement that "for every $1B of premiums, we are required to hold approximately $50M of capital" implies a 55% quota share reinsurance ceding percentage for 2026. This matters because it shows Oscar can grow membership 58% without straining capital. The new $475M revolving credit facility secured in February 2026 provides additional flexibility, and management notes they have "virtually no leverage." The implication is that Oscar can fund its turnaround internally.

Outlook, Management Guidance, and Execution Risk

Management's 2026 guidance represents an aggressive profitability pivot. The $18.7-19B revenue range implies 61% growth at the midpoint, driven by 3M paid members by Q2 (58% increase) and 28% weighted average rate increases. The 82.4-83.4% MLR target represents 450 basis points of improvement, while the 15.8-16.3% SG&A ratio adds another 140 basis points of leverage. The $250-450M operating earnings guidance, a $750M swing from 2025's $396M loss, implies 1.9% operating margins at the midpoint. This matters because it suggests Oscar can achieve profitability while still growing well above market rates.

The guidance assumptions are explicit. Management assumes the enhanced premium tax credits expire, market contraction of 20-30%, and elevated morbidity consistent with 2025 experience plus an incremental increase. They project risk adjustment at 20% of direct premiums, up from 18.5% in 2025, reflecting a younger, healthier membership mix that will require larger transfer payments. This matters because it shows conservatism: they're not banking on a favorable risk adjustment windfall but rather pricing for the worst-case scenario. The 28% rate increase reflects higher market morbidity, elevated trends, and program integrity initiatives.

Execution risk centers on three variables. First, member retention: Mark Bertolini's warning that "people start to use their plans and realize the amount of out-of-pocket that they need to pay" could drive churn patterns similar to pre-ARPA levels of 1-2% monthly. The projection of 3M paid members by Q2 implies 400K lives lost from the 3.4M OEP total, a 12% attrition rate that could accelerate if subsidy expiration creates financial hardship. Second, risk adjustment accuracy: estimating relative healthiness remains an art, and another $275M true-up would erase half the projected 2026 profit. Third, competitive response: if the 28% rate increases attract new entrants or cause existing players to reprice, Oscar's market share gains could reverse.

The ICHRA strategy adds a layer of execution complexity. While the acquisitions create capability, converting employer groups to individual coverage requires changing decades of group insurance purchasing behavior. The Hy-Vee partnership is promising but small; scaling to meaningful contribution will take years. However, if ICHRA adoption accelerates, Oscar's first-mover position could create a new growth vector beyond the ACA's 22 million members, fundamentally expanding the TAM.

Risks and Asymmetries: What Could Break the Thesis

The most material risk is risk adjustment estimation error. The Q4 2025 $275M charge occurred because Oscar's membership was healthier than the broader market, requiring a larger payable. This matters because risk adjustment is a zero-sum game where small miscalculations create massive earnings volatility. With 2026 guidance assuming 20% of premiums will be transferred out (up from 18.5%), a 100 basis point error on $19B revenue equals a $190M swing—enough to turn projected profits into losses. The Wakely report showing market morbidity increased 1.5-2 points provides some external validation, but the opacity of competitor data means Oscar is essentially flying blind on its largest P&L line item.

Member churn from subsidy expiration presents a binary outcome. Richard Blackley expects "less SEP membership this year" and "high nonpayment rates" for members moving from $0 plans to out-of-pocket payments. This matters because Oscar's 2026 guidance assumes 3M paid members by Q2, but if churn exceeds the 1-2% monthly pre-ARPA baseline, Q3 and Q4 membership could fall below the 2M 2025 average, compressing revenue and reversing fixed cost leverage. Mark Bertolini's warning that "most Americans only have $400 in their bank account" suggests the affordability cliff is real. The asymmetry is severe: if retention holds, Oscar beats guidance handily; if it cracks, the 2026 turnaround narrative collapses.

Competitive dynamics could shift rapidly. While Oscar gained share as competitors exited, the 28% rate increases may attract re-entry. Richard Blackley notes the market is "very rational" with no "land grab" pricing, but this could change if a large player like Centene or Elevance decides to sacrifice margins for volume. Oscar's moat is deep but narrow: its technology advantage matters most to digitally-native consumers, but price-sensitive shoppers may still choose cheaper narrow-network plans. The 30% footprint share makes Oscar a target; if competitors underprice by 10-15% in key markets, Oscar could lose the younger, healthier members that drive its risk adjustment strategy.

Operational scaling risk looms large. Growing from 2M to 3M+ members while cutting $60M in administrative costs requires flawless execution. The reduction in force provides half the savings, with the remainder from closing open roles and reducing vendor costs. This matters because Oscar must maintain service quality during rapid expansion. If Oswell's 86% resolution rate drops or provider network adequacy suffers, member satisfaction and retention will decline, undermining the entire thesis. The 60% increase in broker partnerships helps manage distribution but adds complexity to commission structures and oversight.

Valuation Context: Pricing the Turnaround

At $11.84 per share, Oscar trades at a $3.53B market cap, or 0.30x TTM sales of $11.7B. This matters because it prices the stock as a distressed insurer rather than a technology-enabled growth company. The price-to-operating cash flow ratio of 3.22 and price-to-free cash flow of 3.33 reflect the market's skepticism about sustainability of 2025's $1.09B in operating cash flow. However, the enterprise value indicates the market is essentially valuing Oscar's operating business at a deep discount relative to its cash position.

Comparative valuation reveals the disconnect. UnitedHealth trades at 0.54x sales with 2.69% profit margins and 12.54% ROE. Elevance trades at 0.33x sales with 2.84% profit margins and 13.25% ROE. Humana (HUM) trades at 0.16x sales but maintains positive margins. Centene trades at 0.08x sales with -3.79% profit margins, similar to Oscar's -3.79% profit margin but with 19.4% revenue growth versus Oscar's 28%. This matters because Oscar's 2026 guidance implies 1.9% operating margins at the midpoint—roughly in line with mature peers—but on 61% revenue growth. If achieved, a 0.30x sales multiple would be demonstrably low, suggesting 100%+ upside potential.

The balance sheet strength fundamentally changes the risk profile. With $5.5B in cash and investments, $1B in insurance subsidiary surplus, and "virtually no leverage," Oscar has 2-3 years of runway even if 2026 guidance proves optimistic. This matters because it eliminates the existential risk that plagues most money-losing insurers. The $475M credit facility provides additional flexibility for acquisitions or working capital. The implication is that investors are buying a call option on the turnaround with limited downside protection from asset value.

Key metrics to monitor are revenue per member, MLR stability, and SG&A leverage. Oscar's 2026 guidance implies $6,233 in revenue per member (midpoint of $19B on 3M members), up from $5,835 in 2025, reflecting the 28% rate increase partially offset by mix shift to Bronze plans. If revenue per member holds steady while MLR improves to 83%, each 100 basis point improvement flows directly to operating income at 85% incremental margins. This creates a highly levered earnings profile where small operational wins generate large valuation re-rating.

Conclusion: A Technology-Enabled Insurance Turnaround with Asymmetric Risk/Reward

Oscar Health's 2026 narrative hinges on a simple but powerful thesis: a technology platform built for the digital age can create sustainable competitive advantages in a commoditized insurance market. The 2025 reset, which produced a $443M loss, was an industry-wide repricing event that Oscar navigated while improving its cost structure and gaining market share. The 2026 guidance for $250-450M in operating earnings on 61% revenue growth is the mathematical result of 3M members generating $19B in revenue at an 83% MLR and 16% SG&A ratio—metrics that are aggressive but achievable if the technology moat holds.

The central investment case rests on two variables. First, risk adjustment accuracy: if Oscar's 20% payable estimate proves correct, the $750M earnings swing materializes; if market morbidity shifts or competitors game the system, another $275M true-up could erase profits. Second, member retention: if the 3.4M OEP enrollees stabilize at 3M paid members and churn reverts to pre-ARPA 1-2% monthly, the revenue base is secure; if subsidy expiration drives higher nonpayment rates, the entire growth story collapses.

What makes this opportunity asymmetric is the valuation. At 0.30x sales with $5.5B in cash, the market prices Oscar as a failing insurer despite 28% revenue growth and improving margins. If management executes on the 2026 guidance, the stock could re-rate to 0.6-0.8x sales, implying 100-150% upside. If they miss, the cash cushion provides a floor that limits downside. For investors willing to underwrite the risk adjustment and retention risks, Oscar offers a rare combination of hypergrowth, improving margins, and downside protection—a technology company masquerading as a troubled insurer at a price that assumes the worst.